Clinical Trials Logo

Non-Small Cell Lung Cancer clinical trials

View clinical trials related to Non-Small Cell Lung Cancer.

Filter by:

NCT ID: NCT02437136 Completed - Clinical trials for Non-Small Cell Lung Cancer

Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer

Start date: July 2015
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and tolerability of entinostat used in combination with pembrolizumab in patients with Non-small Cell Lung Cancer. Additionally, the purpose of the study is to assess how effective entinostat and pembrolizumab are in combination in patients with Non-small Cell Lung Cancer, Melanoma, and Mismatch-Repair Proficient Colorectal Cancer

NCT ID: NCT02424617 Completed - Clinical trials for Non-Small Cell Lung Cancer

A Study of BGB324(Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer

Start date: March 2015
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase I/2 multi-center open-label study of BGB324 (bemcentinib) in combination with erlotinib in participants with Stage IIIb or Stage IV non-small cell lung cancer. Bemcentinib is a potent selective small molecule inhibitor of Axl, a surface membrane protein kinase receptor which is connected with poor prognosis and acquired resistance to therapy.

NCT ID: NCT02409368 Completed - Clinical trials for Non-Small Cell Lung Cancer

An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC

Checkmate 171
Start date: April 29, 2015
Phase: Phase 2
Study type: Interventional

The purpose of the study is to determine the occurrence of high-grade (CTCAE v4.0 Grades 3-4), treatment-related, select adverse events in patients with advanced or metastatic Squamous Cell Non-Small Cell Lung Cancer (SqNSCLC) with progression of disease during or after at least 1 systemic therapy.

NCT ID: NCT02403271 Completed - Breast Cancer Clinical Trials

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

Start date: March 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1b/2, multi-center study to assess the safety and efficacy of ibrutinib in combination with durvalumab (MEDI4736) in participants with relapsed or refractory solid tumors.

NCT ID: NCT02391480 Completed - Breast Cancer Clinical Trials

A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer

Start date: April 14, 2015
Phase: Phase 1
Study type: Interventional

This is a Phase 1, first-in-human, dose escalation study in participants with advanced solid tumors to determine the pharmacokinetics, maximum tolerated dose and the recommended Phase 2 dose of ABBV-075 at different monotherapy dosing schedules. In addition the study will evaluate the safety. tolerability and the pharmacokinetics of ABBV-075 monotherapy or combination therapy in disease specific expansion cohorts.

NCT ID: NCT02388919 Completed - Clinical trials for Non-small Cell Lung Cancer

Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer(ALTER0303)

ALTER0303
Start date: February 26, 2015
Phase: Phase 2/Phase 3
Study type: Interventional

Evaluate the efficacy and safety of Anlotinib as the 3-line treatment of patients with advanced non-small lung cancer, with placebo control.

NCT ID: NCT02381314 Completed - Melanoma Clinical Trials

Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer

Start date: March 26, 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety of enoblituzumab (MGA271) in combination with Yervoy (ipilimumab) when given to patients with B7-H3-expressing melanoma, squamous cell carcinoma of the head and neck (SCCHN), non small cell lung cancer (NSCLC) and other B7-H3 expressing cancers. The study will also evaluate what is the best dose of enoblituzumab to use when given with ipilimumab. Assessments will also be done to see how the drug acts in the body (pharmacokinetics (PK), pharmacodynamics) and to evaluate potential anti-tumor activity of enoblituzumab in combination with ipilimumab.

NCT ID: NCT02374645 Completed - Clinical trials for Non-Small Cell Lung Cancer

A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC

Start date: April 2015
Phase: Phase 1
Study type: Interventional

This is a Phase 1b, open-label, multicentre study of AZD6094 in combination with gefitinib in patients with epidermal growth factor receptor (EGFR) mutation positive (m+) and progressed on EGFR Tyrosine kinase inhibitor (TKI) treatment.

NCT ID: NCT02369198 Completed - Clinical trials for Non-Small Cell Lung Cancer

MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC

Start date: September 2014
Phase: Phase 1
Study type: Interventional

The first testing of TargomiRs in the human setting: dose-finding studies in patients with recurrent malignant pleural mesothelioma and non-small cell lung cancer

NCT ID: NCT02364999 Completed - Clinical trials for Non-Small Cell Lung Cancer

A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC

Start date: April 2015
Phase: Phase 3
Study type: Interventional

This is a multinational, double-blind, randomized, parallel-group Phase 3 clinical trial evaluating the efficacy and safety of bevacizumab-Pfizer plus paclitaxel and carboplatin versus bevacizumab-EU plus paclitaxel and carboplatin in first-line treatment for patients with advanced (unresectable, locally advanced, recurrent or metastatic) non-squamous NSCLC.